]>Once Daily Valacyclovir for Reducing Viral Shedding in Subjects Newly Diagnosed with Genital Herpes : Table 3
Table 3: Post-hoc Analysis of Patients with Documented Incident Infection—Results from the First Treatment Period.

HSV-2 AntibodyHSV-2 Antibody
Negativea 𝑛 = 4 Positive 𝑛 = 3 1

Percent days with total shedding, Mean (SD %)   𝑃 -valueb43.8 (18.6 )11.2 (14.8)
𝑃 < . 0 0 1

Percent days with subclinical shedding, Mean (SD %)   𝑃 -valueb31.9 (12.8 )8.9 (14.1)
𝑃 = . 0 0 2

Proportion of subjects recurrence-freec, 𝑛 (%)0 (0)19 (61)

aThis group includes 3 subjects who were HSV-1 and HSV-2 seronegative, and one subject who was HSV-1 seropositive and HSV-2 seronegative. bThis was an exploratory analysis; 𝑃 -values should be regarded only as a rough guide to the magnitude of differences between groups. cThis difference was statistically significant ( 𝑃 = . 0 4 ); however, this was an exploratory analysis.